New Preclinical Data Suggest That Cellectar Biosciences’ PDC Platform Provides Enhanced Outcomes in Combination with External Radiation
October 30, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces data...